Yes, amiodarone can cause bradycardia, and it’s one of the drug’s most well-known cardiac side effects. In large clinical trials, about 2.4% of patients on amiodarone developed bradycardia severe enough to require stopping the medication within the first year, compared to 0.8% on placebo. While that number may sound small, the risk climbs significantly in certain patient groups, and the drug’s unusually long half-life means the slow heart rate can persist for weeks to months after discontinuation.
Why Amiodarone Slows the Heart
Amiodarone is classified as an antiarrhythmic drug, meaning its entire purpose is to alter the heart’s electrical activity. It does this through multiple mechanisms simultaneously, which is part of what makes it so effective for dangerous rhythm problems but also why it produces such a wide range of side effects.
The most relevant mechanism for bradycardia is its effect on potassium channels. By blocking these channels, amiodarone prolongs the time cardiac tissue needs to “reset” between beats, slowing the overall rate. This blocking action is “use-dependent,” meaning it intensifies as the heart rate increases. That property is useful for controlling fast rhythms, but in some patients, the slowing effect overshoots and drops the heart rate too low. Amiodarone also has beta-blocker-like and calcium-channel-blocker-like properties baked into its pharmacology, both of which independently contribute to a slower heart rate by dampening the electrical signals in the heart’s natural pacemaker (the sinus node) and the relay station between the upper and lower chambers (the AV node).
These effects are more pronounced with long-term oral use than with short-term intravenous use. When given intravenously, the drug’s slowing effect on conduction is largely limited to the AV node. With chronic oral therapy, it extends to nearly all cardiac tissue, which is why bradycardia tends to become a bigger concern over time rather than appearing only during the initial loading phase.
When Bradycardia Typically Appears
Bradycardia can show up at any point during amiodarone therapy. During intravenous loading (often used in hospital settings for life-threatening arrhythmias), bradycardia and low blood pressure are recognized acute risks. During oral loading, which involves high daily doses for the first one to three weeks, bradycardia is also listed among the common side effects alongside QT prolongation and gastrointestinal problems.
What makes amiodarone unusual compared to most medications is its extraordinarily long half-life, measured in weeks rather than hours. Full clinical effects from oral therapy may not appear for up to six weeks. This means bradycardia can develop gradually, sometimes catching patients off guard well after they’ve been on a stable dose. Equally important: if you stop taking amiodarone because of a slow heart rate, the drug’s effects can linger for one to three months as it clears from your body’s tissues. This prolonged washout period is something both patients and their doctors need to plan around.
Who Faces Higher Risk
Certain groups are more vulnerable to clinically significant bradycardia from amiodarone. A study of elderly patients with atrial fibrillation and a history of heart attack found that amiodarone roughly doubled the odds of developing a slow heart rhythm severe enough to require a permanent pacemaker. Women in that study faced an even steeper risk, with nearly four times the odds of needing a pacemaker compared to those not on amiodarone. Men in the same population had a smaller, statistically less certain increase in risk.
Drug interactions are another major factor. If you’re taking a beta-blocker (like metoprolol or propranolol) or a calcium channel blocker (like diltiazem) alongside amiodarone, the combined effect on heart rate can be additive, pushing it lower than either drug would alone. These combinations don’t just interact through blood levels of the drugs; they stack their slowing effects on the heart’s electrical system directly. Digoxin, another medication commonly prescribed for atrial fibrillation, also independently raises the risk of severe bradycardia when used with amiodarone. Patients undergoing surgery face additional risk, as general and local anesthetics can interact with amiodarone to cause both low blood pressure and bradycardia.
What Bradycardia Feels Like
Bradycardia is generally defined as a heart rate below 50 to 60 beats per minute, though the threshold for concern depends on symptoms. A resting heart rate of 55 bpm with no symptoms is handled very differently from one of 55 bpm with dizziness and fatigue.
Common symptoms of a heart rate that’s too slow include lightheadedness, unusual fatigue, feeling faint or actually fainting, shortness of breath with mild exertion, and difficulty concentrating. Some people notice exercise intolerance, where activities that used to feel manageable suddenly leave them winded. Others experience no symptoms at all and only discover the slow rate during a routine check. If you’re on amiodarone and notice any of these changes, checking your pulse (or using a wearable heart rate monitor) can give you useful information to bring to your doctor.
How It’s Managed
Management depends on the severity. For bradycardia without symptoms and a heart rate still above 40 bpm, the typical approach is to continue the current dose while monitoring more closely. No immediate change is needed, but the trend matters, so your care team will want to track whether the rate is stable or still declining.
If the heart rate drops below 40 bpm without symptoms, a 50% dose reduction is the standard recommendation. After reducing the dose, patients are typically monitored with an event recorder worn for two to four weeks to watch for two things: whether the heart rate improves and whether the arrhythmia the drug was controlling breaks through again. That balance, keeping dangerous fast rhythms suppressed without making the heart too slow, is the central challenge of amiodarone therapy.
When bradycardia causes symptoms like dizziness, fainting, or significant fatigue, the dose is either cut in half or the drug is temporarily stopped. Because amiodarone takes so long to leave the body, improvement after dose reduction or discontinuation is gradual rather than immediate. In patients who still need protection against life-threatening arrhythmias but can’t tolerate the slow heart rate, a permanent pacemaker may be considered. The pacemaker provides a safety net for the slow rate, allowing the patient to continue amiodarone for its anti-arrhythmic benefits.
Monitoring While on Amiodarone
Regular heart rate monitoring is a standard part of amiodarone therapy. Current guidelines from the UK’s NHS Specialist Pharmacy Service recommend flagging any resting heart rate at or below 50 bpm, or at or below 60 bpm if symptoms are present. A rate between 50 and 60 bpm without symptoms calls for continued monitoring rather than immediate intervention, but it should prompt more frequent check-ins.
Beyond periodic office visits, many patients on amiodarone benefit from checking their own pulse at home, either manually or with a wearable device. Tracking the trend over days and weeks is more informative than any single reading. A gradual downward drift in resting heart rate, even if each individual reading looks acceptable, is worth reporting to your prescribing doctor before it becomes symptomatic.